Pay in 4 interest-free payments of $5.97 Learn more
Ships within 48 hours · Estimated delivery Aug 12 - Aug 17
Pharmaceutical GLP1 patches under development: aim to deliver a real GLP1 receptor agonist (such as exendin4 or semaglutide) using microneedle or advanced transdermal technologies, but these remain in preclinical or very early development stages and are not available as approved products
The primary endpoints are alteration of transcriptomic profile of tongue tissue as changes in expression level from baseline to follow-up after 16 weeks of treatment, measured by RNA sequencing, and change in taste sensitivity as detected by chemical gustometry
Description Cagrilintide is an investigational, long-acting synthetic peptide that acts as a dual amylin and calcitonin receptor agonist (DACRA), primarily under development for the treatment of obesity and type 2 diabetes
If this new shot for cellulite proves to be as effective as the clinical trials suggest it is, treating cellulite could be simpler than ever before
